Novavax to Make Multiple Presentations at RSV Vaccines for the World

Conference Will Take Place November 18-20, 2015 in La Jolla, California

GAITHERSBURG, Md., Nov. 16, 2015  -- Novavax, Inc. (NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Novavax representatives will be making multiple oral presentations at the RSV Vaccines for the World conference, November 18-20, 2015 in La Jolla, California.

Poster, presentation titles and presenters are listed below:

• “Biophysical Characterization of an RSV Nanoparticle Vaccine.”
  Oleg Borisov, Ph.D., Director, Analytical Development, Novavax, Inc.

• “Randomized Phase 2 Trial of an RSV F Nanoparticle Vaccine in the Elderly: Epidemiology and Efficacy.”
  Vivek Shinde, M.D., Director, Clinical Development, Novavax, Inc.

• “Phase 2 Trial of an RSV F Nanoparticle Vaccine in Pregnant Women Towards Maternal Immunization.”
  Allison August, M.D., Director, Clinical Research, Novavax, Inc.

• “Sera Derived from Immunization with a Recombinant RSV F-protein Nanoparticle Vaccine Obtained from Cotton Rats and Women of Child-bearing Age Contains Antibodies Competitive with Neutralizing Monoclonals Against Multiple Epitopes.”
  Hanxin Lu, Ph.D., Senior Scientist, Novavax, Inc.

The final conference program is available at: http://www.meetingsmanagement.co.uk/images/stories/pdf/rsvvw-2015-leaflet.pdf

About RSV

RSV is a major respiratory pathogen in infants, children, and adults. RSV infections in adults represent re-infections and are generally mild to moderate in severity, except in persons with high-risk conditions including the elderly and adults with underlying chronic cardiac or pulmonary disease. It is estimated that 2.4 million adults 65 years of age or older are infected with RSV annually in the U.S. leading to as many as 900,000 medical interventions and 14,000 deaths each year.^1-5 RSV is the most common cause of lower respiratory tract infections and the leading viral cause of severe lower respiratory tract disease in infants and young children worldwide, with estimated annual infection and mortality rates of 64 million and 160,000, respectively.⁶ In the US, RSV is the leading cause of hospitalization of infants.⁷ Currently, there is no approved RSV vaccine available.

About Novavax

Novavax, Inc. (NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.

References:

1. Falsey, A.R. et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med, 2005; 352:1749–59; extrapolated to 2015 census population.
    
2. Falsey, A.R. et al. Respiratory Syncytial Virus and Influenza A Infections In The Hospital Elderly. J. Infect Dis,1995;172:389-94
    
3. CDC:  http://www.cdc.gov/rsv/research/us-surveillance.html
    
4. Widmer, K. et al. Rates of Hospitalizations for Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Virus in Older Adults. J Infect Dis, 2012; 206: 56-62.
    
5. Widmer, K. et al. Respiratory Syncytial Virus & Human Metapneumovirus-Associated Emergency Department and Hospital Burden in Adults. Influenza Other Respir Viruses, 2014; 8(3): 347-352.
    
6. Nair, H. et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet, 2010; 375: 1545-1555. 
    
7. Hall, C.B. et al. Respiratory Syncytial Virus-Associated hospitalizations Among Children Less Than 24 Months of Age. Pediatrics, 2013; 132(2): E341-348.

Contact: Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

This email address is being protected from spambots. You need JavaScript enabled to view it.
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
212-845-4271